BioNTech and Bristol Myers Squibb reported promising Phase 2 data for their bispecific antibody pumitamig (BNT327) targeting PD-1 and VEGF in extensive-stage small cell lung cancer (SCLC). The study showed tumor shrinkage in 76% of patients, with 100% disease control at interim analysis. This supports the dosing strategy for an ongoing Phase 3 trial comparing pumitamig plus chemotherapy against standard immunotherapies. The drug’s dual targeting of immune checkpoint and angiogenesis pathways represents an innovative approach in a field with several competitors. The results were presented at the 2025 World Conference on Lung Cancer. Bristol Myers Squibb is partnering with BioNTech in a deal worth up to $3.5 billion through 2028 to co-develop pumitamig.